Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in New Haven, Connecticut. The company focuses on developing therapies for neurologically mediated conditions, primarily targeting chronic cough. Its lead investigational product is Haduvio, an oral extended-release formulation of the small molecule nalbuphine. Trevi is advancing Haduvio through late-stage clinical trials for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (ILD), and refractory chronic cough (RCC). The company operates as a single business segment dedicated to the clinical development of this therapy. By focusing on these specific respiratory and neurological indications, Trevi aims to address conditions that currently have no FDA-approved treatments in the United States.
